 predict that it might address a lot of these other underlying conditions that happen along with periodontal disease. So not just a microbiome impact, but the inflammatory pathways. That underlie many age-related conditions. Rabimiacin is a generic drug, so pharmaceutical companies have little incentive to fund new research. Ahn has received grants to conduct this trial, which could open the door to further studies.